Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine + clofarabine + busulfan
- Development stage
- Phase 2
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
This combination regimen, consisting of gemcitabine, clofarabine, and busulfan (Gem/Clo/Bu), is a myeloablative conditioning treatment developed by the M.D. Anderson Cancer Center for patients undergoing allogeneic hematopoietic stem cell transplantation for refractory lymphomas. Gemcitabine and clofarabine are nucleoside analogs that inhibit DNA polymerase and ribonucleotide reductase, which not only provides direct antineoplastic activity but also inhibits DNA repair mechanisms. This inhibition sensitizes the malignant cells to the DNA-alkylating effects of busulfan, creating a synergistic cytotoxic effect. The regimen is specifically designed to treat aggressive and refractory forms of B-cell non-Hodgkin lymphoma, T-cell non-Hodgkin lymphoma, and Hodgkin lymphoma, aiming to maximize tumor cytoreduction and facilitate successful donor engraftment.
- Other names
- Gem/Clo/Bugemcitabine hydrochlorideclofarabinebusulfan
02
Targets
DNADNA polymerase familyRNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on gemcitabine + clofarabine + busulfan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine + clofarabine + busulfan.